公开(公告)号：US20240199725A1

公开(公告)日：2024-06-20

申请号：US18287139

申请日：2022-04-13

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Sang Taek JUNG ,  Ji Sun LEE ,  Bo Mi KIM

IPC: C07K16/10 ,  G01N33/569

CPC classification number: C07K16/1003 ,  G01N33/56983 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92 ,  G01N2333/165 ,  G01N2469/10

Abstract: The present invention relates to a human antibody against a novel coronavirus and a variant thereof, or an immunologically active fragment of the human antibody. The human antibody against a novel coronavirus and a variant thereof, or an immunologically active fragment of the human antibody can effectively keep COVID-19 virus from infecting a host by binding with high affinity to an RBD region of a spike protein of COVID-19 virus or a variant thereof, may be utilized for preventing or treating COVID-19 virus infection by binding to a variety of all variants of COVID-19 virus with high affinity, and may be advantageously utilized in diagnosis and epidemiological surveys of highly infectious covid-19 virus by enabling rapid diagnosis (detection) of various types of COVID-19 virus.

公开(公告)号：US20230399407A1

公开(公告)日：2023-12-14

申请号：US18035609

申请日：2021-11-03

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Sang Taek JUNG ,  Ji Sun LEE ,  Bo Mi KIM

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/283 ,  C07K16/32 ,  C07K2317/92 ,  C07K2317/31 ,  C07K2317/622

Abstract: The present invention relates to an antibody having enhanced binding affinity for human Fc alpha receptor and a technique for maximizing a mechanism of antibody action by using same. Antibodies specific for Fc alpha receptors or immunologically active fragments thereof according to the present invention are in the form of IgG and bind to Fc alpha receptors of effector cells, especially, neutrophils, which are most abundant in mammals, thereby overcoming the disadvantages of conventional IgA antibodies and maximizing an effector function in various antibody therapeutic agents, which leads to maximizing the mechanism of antibody action (ADCC and ADCP). Thus, various Fc-fused protein therapeutic agents using same can be advantageously utilized as antibody drugs with enhanced effector functions.